Literature DB >> 12895429

Enhanced vasoconstrictor responses in eNOS deficient mice.

Kathryn Lamping1, Frank Faraci.   

Abstract

Previous studies suggest that vasoconstriction is modulated by nitric oxide (NO). Contractions to ET-1 and/or thromboxane may be enhanced during chronic deficiency in expression or activity of NO synthase (NOS). Multiple isoforms of NOS are expressed within the vessel wall and purely pharmacological approaches cannot define the role of each. We tested the hypothesis that vasoconstriction to endothelin-1 (ET-1) and/or the thromboxane mimetic, U46619, is enhanced under conditions of chronic, selective deficiency in endothelial NOS (eNOS-/-) by examining responses in aorta from eNOS-/- mice compared to wild type (eNOS+/+). ET-1 produced dose-dependent contraction of aorta from eNOS+/+ mice that was increased twofold following acute inhibition of all NOS isoforms with N(G)-nitro-L-arginine (L-NNA). In eNOS-/- mice, contractions to ET-1 were increased twofold compared to eNOS+/+. L-NNA had no effect. Although contraction of the aorta to thromboxane mimetic U46619 was increased at lower concentrations, maximal contractions to U46619 were not increased following acute inhibition of NOS or in eNOS-/- mice. These studies provide direct evidence that vasoconstriction to ET-1 and thromboxane is augmented in the face of eNOS deficiency, demonstrating that eNOS normally inhibits vascular contractile responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895429     DOI: 10.1016/s1089-8603(03)00028-4

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  8 in total

Review 1.  Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis.

Authors:  Louis J Ignarro; Claudio Napoli
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

Review 2.  Recent advances in understanding endothelial dysfunction in atherosclerosis.

Authors:  Zhihong Yang; Xiu-Fen Ming
Journal:  Clin Med Res       Date:  2006-03

Review 3.  Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise.

Authors:  Palak P Oza; Khosrow Kashfi
Journal:  Nitric Oxide       Date:  2022-08-24       Impact factor: 4.898

4.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

Review 5.  Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis.

Authors:  Louis J Ignarro; Claudio Napoli
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

6.  Role of CaMKII in Ang-II-dependent small artery remodeling.

Authors:  Anand M Prasad; Pimonrat Ketsawatsomkron; Daniel W Nuno; Olha M Koval; Megan E Dibbern; Ashlee N Venema; Curt D Sigmund; Kathryn G Lamping; Isabella M Grumbach
Journal:  Vascul Pharmacol       Date:  2016-09-20       Impact factor: 5.773

7.  Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats.

Authors:  K Budzyn; R M Ravi; A A Miller; C G Sobey
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

8.  Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells.

Authors:  Anar Dushpanova; Silvia Agostini; Enrica Ciofini; Manuela Cabiati; Valentina Casieri; Marco Matteucci; Silvia Del Ry; Aldo Clerico; Sergio Berti; Vincenzo Lionetti
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.